NIKKEI 225
37,171.78 -907.92 (-2.38%) HANG SENG
16,184.02 -201.85 (-1.23%) CRUDE OIL
84.83 +2.10 (+2.54%) GOLD FUTURES
2,404.10 +6.10 (+0.25%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
50,138.69 +374.14 (+0.75%)
Avidity Biosciences, Inc. (RNA)
After hours:
| Previous close | 23.55 |
| Open | 23.55 |
| Bid | 23.02 x 100 |
| Ask | 23.07 x 100 |
| Day's range | 22.78 - 23.98 |
| 52-week range | 4.82 - 27.66 |
| Volume | |
| Avg. volume | 1,193,664 |
| Market cap | 1.837B |
| Beta (5Y monthly) | 0.77 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences:
- PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 30,800 shares of its common stock and 15,400 restricted stock units ("RSUs") to three (3) new non-executive employees under the Avidity Biosci
- PR Newswire
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced new positive long-term AOC 1001 data from the MARINA open-label extension (MARINA-OLE™) trial showing reversal of disease progression in people living with myotonic dystrophy type 1 (DM1) across multiple endpoints including vHOT, muscle strength and activities of daily living when compared to END-DM1 natur
